Modalities to Deliver Cell Therapy for Treatment of Chronic Limb Threatening Ischemia

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Clinical Therapeutics

Background:

• Chronic limb-threatening ischemia (CLTI) is a severe manifestation of peripheral arterial disease (PAD), leading to high rates of morbidity, mortality, and limb loss.
• Many CLTI patients lack viable revascularization options through traditional surgical or interventional methods.
• Stem cell therapy presents a potential therapeutic alternative for these underserved patients.

Purpose of the Study:

• To review and analyze various cell delivery modalities employed in clinical trials for treating severe peripheral arterial disease (PAD).
• To evaluate the safety, efficacy, and feasibility of direct cell delivery to ischemic limbs in PAD patients.
• To identify critical issues and future directions in optimizing cell therapy delivery for CLTI.

Main Methods:

• Focus on delivery modalities used in clinical trials for cell therapy in severe PAD.
• Examination of local, regional, and combination cell delivery approaches.
• Review of pre-clinical studies and clinical trial data on cell therapy for PAD.

Main Results:

• Direct cell delivery to ischemic limbs has demonstrated safety, efficacy, and feasibility in patients with severe PAD.
• Multiple cell delivery methods have been explored in pre-clinical research and clinical investigations.
• Clinical trials indicate therapeutic benefits of cell therapy for CLTI patients, but treatment methods are not yet standardized.

Conclusions:

• Cell therapy is a viable option for CLTI patients unresponsive to conventional treatments.
• Standardization of cell treatment methods, particularly cell delivery, is crucial for optimizing outcomes.
• Further research is essential to determine the optimal cell delivery approach for maximizing clinical benefits in PAD patients.